查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1929601

亲水性冠状动脉支架市场（按支架类型、药物类型、聚合物材料、支架尺寸、临床用途和最终用户划分），全球预测，2026-2032年

Hydrophilic Coronary Stents Market by Stent Type, Drug Type, Polymer Material, Stent Size, Clinical Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2025年亲水性冠状动脉支架市值为13.2亿美元，预计2026年将成长至14.2亿美元，预计到2032年将达到20.9亿美元，复合年增长率为6.81%。

关键市场统计数据
基准年 2025 13.2亿美元
预计年份：2026年 14.2亿美元
预测年份 2032 20.9亿美元
复合年增长率 (%) 6.81%

本文简要概述了亲水性冠状动脉支架的发展历程，重点介绍了临床创新、监管压力和手术应用趋势。

亲水性冠状动脉支架已从一项小众创新发展成为现代介入性心臟病学中不可或缺的工具。透过将表面工程与临床应用相结合，它们能够减少急性手术併发症并促进血管癒合。涂层化学、聚合物选择和抗增殖药物整合的进步显着提升了支架的性能，而手术和影像辅助技术的进步也优化了支架的配置和长期通畅率。因此，临床医师和采购团队会从即时输送性、生物相容性和后续临床疗效等综合观点来评估支架的选择。

技术创新、采购改革和临床偏好的整合将如何重塑竞争格局和设备差异化

亲水性冠状动脉支架领域的变革是由技术、临床和政策趋势的整合所驱动的，这些趋势共同重新定义了製造商和医疗服务提供者的价值创造。在技​​术方面，亲水性涂层和先进聚合物基质的结合有望提高支架的输送性能并减少内皮损伤。这激发了临床对兼具易用性和良好癒合特性的器械的兴趣。在临床实践中，器械的选择越来越依赖于能够证明器械特性与特定患者群体和病变亚型之间关联性的证据，从而推动了从「一刀切」式选择向精准器械匹配的转变。

评估2025年美国关税对供应链、筹资策略、合约架构和医疗服务提供者采购行为的影响

美国在2025年实施的关税政策给亲水性冠状动脉支架生态系统带来了巨大压力，对製造商、供应商和医疗服务机构的成本、物流和策略都产生了影响。关税提高了进口零件和成品的本地到货成本，迫使製造商重新评估筹资策略、重新谈判供应商合同，并在可能的情况下评估本地生产的替代方案。因此，一些供应商加快了近岸外包的步伐，以降低跨境课税及其带来的前置作业时间波动风险。

全面的细分洞察将支架采用模式与支架类型、药物特性、临床环境、聚合物选择、尺寸和临床环境联繫起来

细分市场分析揭示了临床选择和采购偏好的细微驱动因素。首先，按支架类型，我们分析了裸金属支架和药物释放型支架（DGS）市场，重点阐述了每种支架类型如何对血管再阻塞风险、双联抗血小板治疗持续时间和手术选择产生不同的影响。同时，按药物类型区分，重点在于依Everolimus、紫杉醇、Sirolimus和佐他莫司，着重阐述了每种抗增殖药物如何影响内皮反应谱，并针对具有不同合併症和病变特征的患者亚群调整其适用性。这些药理学差异对临床决策和製造商的研发蓝图至关重要。

全球各地的区域法规环境、采购结构和医疗保健基础设施如何推动不同的采用路径

区域趋势正在影响亲水性冠状动脉支架的获取途径以及创新技术在临床实践中的应用路径。在美洲，先进的手术基础设施、整合的采购集团和完善的报销机制使得三级医疗中心能够快速采用创新器械，而农村和社区医疗机构则面临运营方面的限制，影响其采购决策。该地区不同支付方构成和医院所有权的差异，导致高容量心臟中心和资源匮乏的医疗机构之间的器械采用率存在差异。

分析竞争策略和策略联盟，重点在于技术差异化、证据产生和供应链韧性

业内相关人员在产品开发、临床证据产生和商业性伙伴关係采取了各具特色的方法。一些公司强调专有涂层技术或聚合物工程，以区分药物递送特性或癒合效果。另一些机构则专注于广泛的临床项目，收集不同病变亚型和临床环境下的真实世界数据，从而建立能够吸引介入性心臟病专家和医院采购委员会的临床案例。策略联盟和经销伙伴对于拓展地域覆盖范围仍然至关重要，尤其是在当地监管和报销政策调整需要本地专业知识的地区。

为产业领导者提供切实可行的策略行动，以协调产品创新、供应链永续性和实证实践与医疗服务提供者的优先事项。

为了应对不断变化的临床、监管和供应链压力，产业领导者应优先采取一系列果断行动，使产品开发与医疗服务提供者的需求和采购实践保持一致。首先，投资强而有力的临床证据项目，针对细分框架中所确定的不同亚群和手术场景。在非ST段抬高型心肌梗塞（NSTEMI）、ST段抬高型心肌梗塞（STEMI）和择期手术中展现一致的性能，将显着影响介入性心臟病专家的器械选择。其次，透过供应商多元化、在可行的情况下采用近岸外包以及与高容量设施建立策略库存合作伙伴关係，提高供应链的韧性，从而降低关税和物流波动带来的风险。

一项采用混合方法的研究，结合了临床医生访谈、采购分析和临床检验三角验证，旨在得出可操作的医疗器材见解。

本分析所依据的研究采用了混合方法，结合了有针对性的初步研究和全面的二手资料，以确保获得平衡且具有临床意义的观点。初步研究包括与介入性心臟病专家、医院和门诊采购主管以及行业高管进行结构化访谈和讨论，以收集有关器械选择标准、供应链经验和临床偏好的第一手资讯。这些定性资料辅以手术流程和医院采购模式的深入案例分析，使研究结果与实际操作相结合。

一份权威的综合报告，重点阐述了临床证据、供应弹性以及客製化商业策略在实现持续推广应用方面的相互作用。

总之，亲水性冠状动脉支架处于材料科学、药理学和介入技术的动态交会点，其应用受到细微的临床需求、采购实际情况和不断变化的监管预期的影响。涂层化学和聚合物选择的进步正在显着影响支架的输送性和癒合效果，而药物释放型配方则持续影响支架在特定病变类型和患者群体中的适用性。随着医疗机构越来越重视手术效率和整体手术价值，製造商必须将临床差异化与供应的可预测性和支持服务相结合，以确保支架的持续应用。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 亲水性冠状动脉支架市场（依支架类型划分）

  • 裸金属支架
  • 药物释放型支架

9. 依药物类型分類的亲水性冠状动脉支架市场

  • Everolimus
  • 紫杉醇
  • Sirolimus
  • 佐他罗莫司

10. 依聚合物材料分類的亲水性冠状动脉支架市场

  • 可生物降解聚合物
  • 耐用聚合物

11. 依支架尺寸分類的亲水性冠状动脉支架市场

  • 18至28毫米
  • 超过 28 毫米
  • 小于18毫米

12. 亲水性冠状动脉支架市场（依临床应用划分）

  • 急性冠状动脉症候群
    • 非ST段上升型心肌梗塞（NSTEMI）
    • STEMI
    • 不稳定型心绞痛
  • 稳定性心绞痛

第十三章 亲水性冠状动脉支架市场（依最终用户划分）

  • 门诊手术中心
  • 医院
    • 私立医院
    • 公立医院

第十四章 亲水性冠状动脉支架市场（依地区划分）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章 亲水性冠状动脉支架市场（依类别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章 各国亲水性冠状动脉支架市场

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

17. 美国亲水性冠状动脉支架市场

第十八章：中国亲水性冠状动脉支架市场

第十九章 竞争情势

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Abbott Laboratories
  • Apollo Endosurgery, Inc.
  • B. Braun Melsungen AG
  • Biotronik SE & Co. KG
  • Boston Scientific Corporation
  • Cook Medical LLC
  • Edwards Lifesciences Corporation
  • Endologix LLC
  • Hansen Medical, Inc.
  • Invuity, Inc.
  • Johnson & Johnson Services, Inc.
  • Lepu Medical Technology（Beijing）Co., Ltd.
  • Livar Stent Co., Ltd.
  • Medtronic plc
  • Meril Life Sciences Pvt. Ltd.
  • MicroPort Scientific Corporation
  • Philips Healthcare
  • Relievant Medsystems, Inc.
  • Shanghai MicroPort Medical（Group）Co., Ltd.
  • Shanghai Shape Memory Alloy Co., Ltd.
  • Siemens Healthineers AG
  • Stryker Corporation
  • Terumo Corporation
  • Translumina GmbH & Co. KG
Product Code: MRR-0A3806951844

The Hydrophilic Coronary Stents Market was valued at USD 1.32 billion in 2025 and is projected to grow to USD 1.42 billion in 2026, with a CAGR of 6.81%, reaching USD 2.09 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.32 billion
Estimated Year [2026] USD 1.42 billion
Forecast Year [2032] USD 2.09 billion
CAGR (%) 6.81%

A concise framing of hydrophilic coronary stent evolution highlighting clinical innovation, regulatory pressure, and procedural adoption dynamics

Hydrophilic coronary stents have matured from niche innovations into essential tools within contemporary interventional cardiology, combining surface engineering with clinical intent to reduce acute procedural complications and improve vascular healing. Advances in coating chemistry, polymer choices, and antiproliferative drug integration have shifted device performance profiles, while procedural techniques and imaging adjuncts have evolved to optimize deployment and long-term patency. As a result, clinicians and procurement teams assess stent selection through an integrated lens of immediate deliverability, biocompatibility, and downstream clinical outcomes.

Concurrently, regulatory scrutiny and payer expectations are shaping product lifecycles, demanding robust clinical evidence and demonstrable value across heterogeneous care settings. Hospitals and ambulatory surgery centers have refined their device evaluation pathways to account for device handling, inventory turnover, and the relative ease of transition between stent platforms during complex procedures. This increased emphasis on total procedural value has pressured developers to prioritize both clinical differentiation and supply consistency.

Moreover, incremental innovations in drug formulations and polymer technologies continue to influence clinician preference and patient outcomes. These iterative improvements are prompting device-makers to consider not only efficacy but also logistical factors such as sterilization compatibility, shelf life, and cross-compatibility with delivery systems. Together, these forces create a dynamic environment in which hydrophilic coronary stents must demonstrate clear operational and clinical benefits to gain traction across diverse healthcare infrastructures.

How converging technological advances, procurement reforms, and clinical preferences are reshaping competitive dynamics and device differentiation

Transformation within the hydrophilic coronary stent landscape is being driven by convergent technological, clinical, and policy trends that collectively redefine value creation for manufacturers and care providers. Technologically, the integration of hydrophilic coatings with advanced polymer matrices has improved deliverability and may reduce endothelial trauma, thereby shifting clinical conversations toward devices that combine ease of use with favorable healing profiles. In clinical practice, adoption is increasingly shaped by evidence linking device characteristics to specific patient cohorts and lesion subsets, prompting a move away from one-size-fits-all selection toward precision device matching.

Policy and procurement mechanisms are also in flux. Value-based purchasing programs and hospital group purchasing negotiations emphasize demonstrable outcomes and total cost of ownership, incentivizing collaborations between device innovators and provider networks. Supply-chain resilience has emerged as a strategic priority, with manufacturers diversifying sourcing and manufacturing footprints to mitigate disruptions and ensure predictable supply. As a result, partnerships that bundle clinical training, device analytics, and post-market surveillance are gaining favor, because they address both clinical adoption barriers and institutional risk management.

Finally, the competitive landscape has prompted a wave of product differentiation that centers on drug-eluting profiles, polymer biodegradability, and stent geometries optimized for complex anatomies. These shifts have strengthened the role of targeted clinical evidence and real-world performance data in procurement decisions, leading to iterative cycles of device refinement and focused market entry strategies that respond directly to clinician feedback and hospital procurement criteria.

Assessment of the 2025 United States tariff effects on supply chains, sourcing strategies, contractual frameworks, and provider purchasing behavior

The imposition of United States tariffs in 2025 has introduced notable pressures across the hydrophilic coronary stent ecosystem, imposing cost, logistical, and strategic implications for manufacturers, suppliers, and provider organizations. Tariffs have elevated the landed cost of imported components and finished devices, prompting manufacturers to reassess sourcing strategies, renegotiate supplier contracts, and evaluate local manufacturing alternatives where feasible. Consequently, some suppliers accelerated nearshoring initiatives to reduce exposure to cross-border levies and associated lead-time variability.

For manufacturers that rely on specialized raw materials or coating chemistries sourced internationally, tariffs have compressed margins or required selective repositioning of product portfolios to protect supplier relationships and maintain price competitiveness. In response, several producers have intensified supplier diversification efforts and sought alternative material formulations that either avoid tariffed categories or can be sourced from non-affected jurisdictions. These efforts were accompanied by operational investments to improve yield and reduce waste, thereby offsetting some tariff-driven cost increases.

Healthcare providers have experienced indirect effects through procurement negotiations and inventory management. Purchasing teams have pressed vendors for price relief, bundled service agreements, and longer-term supply commitments to stabilize device availability and control episodic cost pressures. In parallel, contracting strategies have emphasized multi-year agreements and contingency clauses that account for tariff variability, while clinical teams prioritized devices with proven deliverability to limit procedural complexity that could magnify cost impacts.

Regulatory and reimbursement environments have further amplified the tariff effect by tightening cost-containment expectations. Payers increasingly evaluated the comparative clinical benefits relative to total procedural expenditure, encouraging device suppliers to articulate clear value propositions. In summary, the 2025 tariffs accelerated supply-chain reconfiguration, encouraged sourcing agility, and reshaped contract frameworks across the industry, catalyzing strategic responses that prioritize resilience and demonstrable clinical value.

Comprehensive segmentation-driven insights connecting stent types, drug profiles, clinical contexts, polymer choices, sizing, and care settings to adoption patterns

Segmentation insights reveal nuanced drivers of clinical choice and procurement preference, beginning with stent type where the market is analyzed across Bare-Metal Stent and Drug-Eluting Stent and each category brings distinct implications for restenosis risk, dual antiplatelet therapy duration, and procedural selection. In parallel, drug-type differentiation focuses on Everolimus, Paclitaxel, Sirolimus, and Zotarolimus, with each antiproliferative agent influencing endothelial response profiles and tailoring suitability for patient subgroups with varying comorbidities and lesion characteristics. These pharmacologic distinctions are central to clinical decision-making and to manufacturers' development roadmaps.

Clinical application segmentation distinguishes Acute Coronary Syndrome and Stable Angina as primary therapeutic contexts, with the Acute Coronary Syndrome category further dissected into NSTEMI, STEMI, and Unstable Angina to reflect heterogeneous procedural urgency and lesion complexity. This granularity clarifies how device attributes such as deliverability, rapid deployment, and thrombogenicity bear differently on emergent versus elective interventions. Polymer material choices are another critical axis, compared across Biodegradable Polymer and Durable Polymer, since polymer behavior affects drug elution kinetics, inflammatory response, and medium-term vessel healing.

Stent size segmentation-18 To 28 Mm, Over 28 Mm, and Under 18 Mm-captures anatomical fit considerations and the engineering trade-offs between radial strength and flexibility. End-user segmentation contrasts Ambulatory Surgical Center and Hospital settings, with Hospital further divided into Private Hospital and Public Hospital, highlighting differences in purchasing cycles, procedural throughput, and capital constraints that influence product adoption. Taken together, these segmentation lenses offer a multidimensional framework for understanding clinical adoption patterns, procurement preferences, and the technical choices manufacturers must prioritize to address distinct user needs.

How regional regulatory environments, procurement structures, and healthcare infrastructure drive differentiated adoption pathways across global regions

Regional dynamics shape both access to hydrophilic coronary stents and the pathways through which innovations achieve clinical traction, beginning with the Americas where advanced procedural infrastructure, consolidated purchasing groups, and established reimbursement frameworks enable rapid incorporation of device innovations into tertiary centers, while rural and community settings present operational constraints that influence procurement decisions. In this region, variations in payer mix and hospital ownership models create differentiated adoption speeds between high-volume cardiology centers and resource-constrained facilities.

Europe, Middle East & Africa present a heterogeneous landscape where regulatory harmonization in some jurisdictions coexists with fragmented procurement practices in others, producing diverse entry strategies for device manufacturers. Public hospital procurement in several countries exerts downward price pressure, yet centers of clinical excellence and private hospitals often act as early adopters of advanced device platforms, especially where evidence demonstrates procedural or post-procedural efficiencies. Logistics and distribution networks in this combined region require flexible supply arrangements to accommodate cross-border regulatory nuances and varied reimbursement policies.

Asia-Pacific encompasses both highly developed health systems and rapidly expanding access in emerging economies, creating dual pathways for adoption. Leading tertiary hospitals in urban centers frequently participate in clinical evaluations and can catalyze regional diffusion, while expanding ambulatory surgical infrastructure and growing cardiology service lines in secondary cities create new points of care for device use. Across this region, local manufacturing partnerships, regulatory approvals tailored to national requirements, and cost-sensitive procurement are central determinants of how quickly new hydrophilic stent innovations become standard practice.

Profiling competitive approaches and strategic alignments that emphasize technological differentiation, evidence generation, and supply-chain resilience

Industry participants have adopted distinct approaches to product development, clinical evidence generation, and commercial partnerships, with some companies emphasizing proprietary coating technologies and polymer engineering to differentiate on deliverability and healing profiles. Other organizations focus efforts on broad clinical programs that generate real-world performance data across diverse lesion subsets and care settings, creating clinical narratives that resonate with interventional cardiologists and hospital purchasing committees. Strategic alliances and distribution partnerships remain critical to expanding geographic reach, particularly where local regulatory navigation and reimbursement alignment require on-the-ground expertise.

Competition has also centered on lifecycle management, where incremental device upgrades and platform extensions reduce barriers to clinician transition while preserving existing capital equipment compatibility. Several firms have invested in training and proctoring programs to accelerate adoption, recognizing that clinician familiarity with delivery systems materially influences procedural efficiency. Meanwhile, quality and manufacturing consistency have become non-negotiable as providers prioritize supply reliability amid global procurement pressures.

Finally, new entrants and established manufacturers alike are exploring vertical integration strategies spanning coating suppliers, delivery system manufacturers, and clinical-support services. By controlling more elements of the value chain, these organizations aim to deliver bundled solutions that simplify procurement, shorten onboarding timelines, and provide measurable improvements in procedural outcomes and operational predictability.

Pragmatic strategic actions for industry leaders to align product innovation, supply resilience, and evidence generation with provider priorities

To navigate evolving clinical, regulatory, and supply-chain pressures, industry leaders should prioritize a set of decisive actions that align product development with provider needs and procurement realities. First, invest in robust clinical evidence programs that target the distinct subpopulations and procedural contexts identified in the segmentation framework; demonstrating consistent performance across NSTEMI, STEMI, and elective interventions will materially influence device preference among interventional cardiologists. Second, accelerate supply-chain resilience through supplier diversification, nearshoring where practical, and strategic inventory partnerships with high-volume centers to mitigate tariff and logistics volatility.

Third, tailor commercial offers to the end-user profile by developing differentiated value propositions for Ambulatory Surgical Center adoption versus Hospital settings, with specific contractual terms that address throughput, training, and service commitments. Fourth, prioritize polymer and drug formulation innovation that balances long-term vessel healing with clinician-handling preferences, while investing in incremental device ergonomics to reduce procedural complexity. Fifth, enhance post-market surveillance capabilities and real-world data collection to substantiate claims around deliverability, healing, and complication rates, thereby strengthening reimbursement conversations and procurement negotiations.

Lastly, foster collaborative relationships with clinical leaders and payers to co-develop pathways that align device selection with patient outcomes and cost-efficiency goals. By integrating clinical training, demonstrable evidence, and resilient supply practices into commercial strategies, manufacturers and distributors can secure durable partnerships and ensure sustained adoption across heterogeneous care environments.

A mixed-methods research approach combining clinician interviews, procurement analysis, and clinical evidence triangulation to produce actionable device insights

The research underpinning this analysis employed a mixed-methods approach combining targeted primary research with comprehensive secondary source synthesis to ensure balanced, clinically informed perspectives. Primary research included structured interviews and discussions with interventional cardiologists, procurement leaders in hospital and ambulatory settings, and industry executives to capture firsthand insights on device selection criteria, supply-chain experiences, and clinical preferences. These qualitative inputs were supplemented by detailed case reviews of procedural workflows and hospital procurement models to contextualize findings within operational realities.

Secondary research involved systematic review of peer-reviewed clinical literature, regulatory filings, and publicly available clinical registries to validate mechanistic claims regarding stent coatings, polymer behaviors, and drug-elution profiles. To maintain analytical rigor, triangulation methods were applied, cross-referencing clinical evidence with practitioner insights and supply-chain observations to identify consistent patterns and reconcile divergent viewpoints. The methodology also included comparative analysis of regional regulatory pathways and procurement frameworks to ensure that recommendations reflect practical adoption constraints across geographies.

Data synthesis emphasized transparency regarding source provenance and the limitations inherent in any evidence base, particularly where long-term comparative outcome data are limited. Throughout the process, methodological choices prioritized reproducibility and relevance to decision-makers seeking actionable intelligence on product development, commercial strategy, and clinical adoption pathways.

A conclusive synthesis emphasizing the interplay of clinical evidence, supply resilience, and tailored commercial strategies for durable adoption

In sum, hydrophilic coronary stents occupy a dynamic intersection of material science, pharmacology, and interventional technique, with adoption shaped by nuanced clinical needs, procurement realities, and evolving regulatory expectations. Advances in coating chemistry and polymer selection have materially influenced deliverability and healing considerations, while drug-eluting formulations continue to define device suitability across specific lesion types and patient profiles. As providers place greater emphasis on procedural efficiency and total procedural value, manufacturers must couple clinical differentiation with supply predictability and supportive services to secure durable adoption.

Regional and end-user heterogeneity means that no single commercial playbook will fit all contexts. Rather, success will stem from adaptive strategies that align evidence generation with the clinical segments and care settings most likely to derive tangible benefit. Moreover, external pressures such as tariff-driven supply-chain shifts underscore the importance of resilient sourcing strategies and flexible contracting frameworks. By centering decisions on demonstrable clinical outcomes, operational compatibility, and robust post-market surveillance, stakeholders can navigate the complexities of the current environment and position innovations to deliver measurable improvements in patient care and institutional performance.

Ultimately, the devices and strategies that combine clinical credibility, logistical reliability, and clear value propositions will be best positioned to influence procurement decisions and to support clinicians in delivering consistent, high-quality interventional care.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Hydrophilic Coronary Stents Market, by Stent Type

  • 8.1. Bare-Metal Stent
  • 8.2. Drug-Eluting Stent

9. Hydrophilic Coronary Stents Market, by Drug Type

  • 9.1. Everolimus
  • 9.2. Paclitaxel
  • 9.3. Sirolimus
  • 9.4. Zotarolimus

10. Hydrophilic Coronary Stents Market, by Polymer Material

  • 10.1. Biodegradable Polymer
  • 10.2. Durable Polymer

11. Hydrophilic Coronary Stents Market, by Stent Size

  • 11.1. 18 To 28 Mm
  • 11.2. Over 28 Mm
  • 11.3. Under 18 Mm

12. Hydrophilic Coronary Stents Market, by Clinical Application

  • 12.1. Acute Coronary Syndrome
    • 12.1.1. NSTEMI
    • 12.1.2. STEMI
    • 12.1.3. Unstable Angina
  • 12.2. Stable Angina

13. Hydrophilic Coronary Stents Market, by End User

  • 13.1. Ambulatory Surgical Center
  • 13.2. Hospital
    • 13.2.1. Private Hospital
    • 13.2.2. Public Hospital

14. Hydrophilic Coronary Stents Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Hydrophilic Coronary Stents Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Hydrophilic Coronary Stents Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Hydrophilic Coronary Stents Market

18. China Hydrophilic Coronary Stents Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Abbott Laboratories
  • 19.6. Apollo Endosurgery, Inc.
  • 19.7. B. Braun Melsungen AG
  • 19.8. Biotronik SE & Co. KG
  • 19.9. Boston Scientific Corporation
  • 19.10. Cook Medical LLC
  • 19.11. Edwards Lifesciences Corporation
  • 19.12. Endologix LLC
  • 19.13. Hansen Medical, Inc.
  • 19.14. Invuity, Inc.
  • 19.15. Johnson & Johnson Services, Inc.
  • 19.16. Lepu Medical Technology (Beijing) Co., Ltd.
  • 19.17. Livar Stent Co., Ltd.
  • 19.18. Medtronic plc
  • 19.19. Meril Life Sciences Pvt. Ltd.
  • 19.20. MicroPort Scientific Corporation
  • 19.21. Philips Healthcare
  • 19.22. Relievant Medsystems, Inc.
  • 19.23. Shanghai MicroPort Medical (Group) Co., Ltd.
  • 19.24. Shanghai Shape Memory Alloy Co., Ltd.
  • 19.25. Siemens Healthineers AG
  • 19.26. Stryker Corporation
  • 19.27. Terumo Corporation
  • 19.28. Translumina GmbH & Co. KG

LIST OF FIGURES

  • FIGURE 1. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL HYDROPHILIC CORONARY STENTS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY STENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY DRUG TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY POLYMER MATERIAL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY STENT SIZE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY CLINICAL APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES HYDROPHILIC CORONARY STENTS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA HYDROPHILIC CORONARY STENTS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY STENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY BARE-METAL STENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY BARE-METAL STENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY BARE-METAL STENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY DRUG-ELUTING STENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY DRUG-ELUTING STENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY DRUG-ELUTING STENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY EVEROLIMUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY EVEROLIMUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY EVEROLIMUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY PACLITAXEL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY PACLITAXEL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY PACLITAXEL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY SIROLIMUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY SIROLIMUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY SIROLIMUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY ZOTAROLIMUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY ZOTAROLIMUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY ZOTAROLIMUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY POLYMER MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY BIODEGRADABLE POLYMER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY BIODEGRADABLE POLYMER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY BIODEGRADABLE POLYMER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY DURABLE POLYMER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY DURABLE POLYMER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY DURABLE POLYMER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY STENT SIZE, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY 18 TO 28 MM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY 18 TO 28 MM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY 18 TO 28 MM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY OVER 28 MM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY OVER 28 MM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY OVER 28 MM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY UNDER 18 MM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY UNDER 18 MM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY UNDER 18 MM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY ACUTE CORONARY SYNDROME, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY ACUTE CORONARY SYNDROME, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY ACUTE CORONARY SYNDROME, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY ACUTE CORONARY SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY NSTEMI, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY NSTEMI, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY NSTEMI, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY STEMI, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY STEMI, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY STEMI, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY UNSTABLE ANGINA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY UNSTABLE ANGINA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY UNSTABLE ANGINA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY STABLE ANGINA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY STABLE ANGINA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY STABLE ANGINA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY AMBULATORY SURGICAL CENTER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY AMBULATORY SURGICAL CENTER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY AMBULATORY SURGICAL CENTER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY PRIVATE HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY PRIVATE HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY PRIVATE HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY PUBLIC HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY PUBLIC HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY PUBLIC HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. AMERICAS HYDROPHILIC CORONARY STENTS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 72. AMERICAS HYDROPHILIC CORONARY STENTS MARKET SIZE, BY STENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 73. AMERICAS HYDROPHILIC CORONARY STENTS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS HYDROPHILIC CORONARY STENTS MARKET SIZE, BY POLYMER MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS HYDROPHILIC CORONARY STENTS MARKET SIZE, BY STENT SIZE, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS HYDROPHILIC CORONARY STENTS MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS HYDROPHILIC CORONARY STENTS MARKET SIZE, BY ACUTE CORONARY SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS HYDROPHILIC CORONARY STENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS HYDROPHILIC CORONARY STENTS MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 80. NORTH AMERICA HYDROPHILIC CORONARY STENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA HYDROPHILIC CORONARY STENTS MARKET SIZE, BY STENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA HYDROPHILIC CORONARY STENTS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA HYDROPHILIC CORONARY STENTS MARKET SIZE, BY POLYMER MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA HYDROPHILIC CORONARY STENTS MARKET SIZE, BY STENT SIZE, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA HYDROPHILIC CORONARY STENTS MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA HYDROPHILIC CORONARY STENTS MARKET SIZE, BY ACUTE CORONARY SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA HYDROPHILIC CORONARY STENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA HYDROPHILIC CORONARY STENTS MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA HYDROPHILIC CORONARY STENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA HYDROPHILIC CORONARY STENTS MARKET SIZE, BY STENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. LATIN AMERICA HYDROPHILIC CORONARY STENTS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA HYDROPHILIC CORONARY STENTS MARKET SIZE, BY POLYMER MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA HYDROPHILIC CORONARY STENTS MARKET SIZE, BY STENT SIZE, 2018-2032 (USD MILLION)
  • TABLE 94. LATIN AMERICA HYDROPHILIC CORONARY STENTS MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA HYDROPHILIC CORONARY STENTS MARKET SIZE, BY ACUTE CORONARY SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA HYDROPHILIC CORONARY STENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA HYDROPHILIC CORONARY STENTS MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE, MIDDLE EAST & AFRICA HYDROPHILIC CORONARY STENTS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA HYDROPHILIC CORONARY STENTS MARKET SIZE, BY STENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA HYDROPHILIC CORONARY STENTS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA HYDROPHILIC CORONARY STENTS MARKET SIZE, BY POLYMER MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA HYDROPHILIC CORONARY STENTS MARKET SIZE, BY STENT SIZE, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA HYDROPHILIC CORONARY STENTS MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA HYDROPHILIC CORONARY STENTS MARKET SIZE, BY ACUTE CORONARY SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA HYDROPHILIC CORONARY STENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA HYDROPHILIC CORONARY STENTS MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE HYDROPHILIC CORONARY STENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE HYDROPHILIC CORONARY STENTS MARKET SIZE, BY STENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE HYDROPHILIC CORONARY STENTS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE HYDROPHILIC CORONARY STENTS MARKET SIZE, BY POLYMER MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE HYDROPHILIC CORONARY STENTS MARKET SIZE, BY STENT SIZE, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE HYDROPHILIC CORONARY STENTS MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE HYDROPHILIC CORONARY STENTS MARKET SIZE, BY ACUTE CORONARY SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE HYDROPHILIC CORONARY STENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE HYDROPHILIC CORONARY STENTS MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 116. MIDDLE EAST HYDROPHILIC CORONARY STENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. MIDDLE EAST HYDROPHILIC CORONARY STENTS MARKET SIZE, BY STENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. MIDDLE EAST HYDROPHILIC CORONARY STENTS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST HYDROPHILIC CORONARY STENTS MARKET SIZE, BY POLYMER MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 120. MIDDLE EAST HYDROPHILIC CORONARY STENTS MARKET SIZE, BY STENT SIZE, 2018-2032 (USD MILLION)
  • TABLE 121. MIDDLE EAST HYDROPHILIC CORONARY STENTS MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 122. MIDDLE EAST HYDROPHILIC CORONARY STENTS MARKET SIZE, BY ACUTE CORONARY SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 123. MIDDLE EAST HYDROPHILIC CORONARY STENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 124. MIDDLE EAST HYDROPHILIC CORONARY STENTS MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 125. AFRICA HYDROPHILIC CORONARY STENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. AFRICA HYDROPHILIC CORONARY STENTS MARKET SIZE, BY STENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. AFRICA HYDROPHILIC CORONARY STENTS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. AFRICA HYDROPHILIC CORONARY STENTS MARKET SIZE, BY POLYMER MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 129. AFRICA HYDROPHILIC CORONARY STENTS MARKET SIZE, BY STENT SIZE, 2018-2032 (USD MILLION)
  • TABLE 130. AFRICA HYDROPHILIC CORONARY STENTS MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 131. AFRICA HYDROPHILIC CORONARY STENTS MARKET SIZE, BY ACUTE CORONARY SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 132. AFRICA HYDROPHILIC CORONARY STENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 133. AFRICA HYDROPHILIC CORONARY STENTS MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC HYDROPHILIC CORONARY STENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC HYDROPHILIC CORONARY STENTS MARKET SIZE, BY STENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC HYDROPHILIC CORONARY STENTS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC HYDROPHILIC CORONARY STENTS MARKET SIZE, BY POLYMER MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC HYDROPHILIC CORONARY STENTS MARKET SIZE, BY STENT SIZE, 2018-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC HYDROPHILIC CORONARY STENTS MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC HYDROPHILIC CORONARY STENTS MARKET SIZE, BY ACUTE CORONARY SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC HYDROPHILIC CORONARY STENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC HYDROPHILIC CORONARY STENTS MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 144. ASEAN HYDROPHILIC CORONARY STENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. ASEAN HYDROPHILIC CORONARY STENTS MARKET SIZE, BY STENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. ASEAN HYDROPHILIC CORONARY STENTS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. ASEAN HYDROPHILIC CORONARY STENTS MARKET SIZE, BY POLYMER MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 148. ASEAN HYDROPHILIC CORONARY STENTS MARKET SIZE, BY STENT SIZE, 2018-2032 (USD MILLION)
  • TABLE 149. ASEAN HYDROPHILIC CORONARY STENTS MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 150. ASEAN HYDROPHILIC CORONARY STENTS MARKET SIZE, BY ACUTE CORONARY SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 151. ASEAN HYDROPHILIC CORONARY STENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 152. ASEAN HYDROPHILIC CORONARY STENTS MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 153. GCC HYDROPHILIC CORONARY STENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. GCC HYDROPHILIC CORONARY STENTS MARKET SIZE, BY STENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. GCC HYDROPHILIC CORONARY STENTS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. GCC HYDROPHILIC CORONARY STENTS MARKET SIZE, BY POLYMER MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 157. GCC HYDROPHILIC CORONARY STENTS MARKET SIZE, BY STENT SIZE, 2018-2032 (USD MILLION)
  • TABLE 158. GCC HYDROPHILIC CORONARY STENTS MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 159. GCC HYDROPHILIC CORONARY STENTS MARKET SIZE, BY ACUTE CORONARY SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 160. GCC HYDROPHILIC CORONARY STENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. GCC HYDROPHILIC CORONARY STENTS MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPEAN UNION HYDROPHILIC CORONARY STENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPEAN UNION HYDROPHILIC CORONARY STENTS MARKET SIZE, BY STENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPEAN UNION HYDROPHILIC CORONARY STENTS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPEAN UNION HYDROPHILIC CORONARY STENTS MARKET SIZE, BY POLYMER MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPEAN UNION HYDROPHILIC CORONARY STENTS MARKET SIZE, BY STENT SIZE, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPEAN UNION HYDROPHILIC CORONARY STENTS MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPEAN UNION HYDROPHILIC CORONARY STENTS MARKET SIZE, BY ACUTE CORONARY SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPEAN UNION HYDROPHILIC CORONARY STENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPEAN UNION HYDROPHILIC CORONARY STENTS MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 171. BRICS HYDROPHILIC CORONARY STENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. BRICS HYDROPHILIC CORONARY STENTS MARKET SIZE, BY STENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. BRICS HYDROPHILIC CORONARY STENTS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. BRICS HYDROPHILIC CORONARY STENTS MARKET SIZE, BY POLYMER MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 175. BRICS HYDROPHILIC CORONARY STENTS MARKET SIZE, BY STENT SIZE, 2018-2032 (USD MILLION)
  • TABLE 176. BRICS HYDROPHILIC CORONARY STENTS MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 177. BRICS HYDROPHILIC CORONARY STENTS MARKET SIZE, BY ACUTE CORONARY SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 178. BRICS HYDROPHILIC CORONARY STENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 179. BRICS HYDROPHILIC CORONARY STENTS MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 180. G7 HYDROPHILIC CORONARY STENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. G7 HYDROPHILIC CORONARY STENTS MARKET SIZE, BY STENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. G7 HYDROPHILIC CORONARY STENTS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. G7 HYDROPHILIC CORONARY STENTS MARKET SIZE, BY POLYMER MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 184. G7 HYDROPHILIC CORONARY STENTS MARKET SIZE, BY STENT SIZE, 2018-2032 (USD MILLION)
  • TABLE 185. G7 HYDROPHILIC CORONARY STENTS MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 186. G7 HYDROPHILIC CORONARY STENTS MARKET SIZE, BY ACUTE CORONARY SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 187. G7 HYDROPHILIC CORONARY STENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 188. G7 HYDROPHILIC CORONARY STENTS MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 189. NATO HYDROPHILIC CORONARY STENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. NATO HYDROPHILIC CORONARY STENTS MARKET SIZE, BY STENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. NATO HYDROPHILIC CORONARY STENTS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. NATO HYDROPHILIC CORONARY STENTS MARKET SIZE, BY POLYMER MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 193. NATO HYDROPHILIC CORONARY STENTS MARKET SIZE, BY STENT SIZE, 2018-2032 (USD MILLION)
  • TABLE 194. NATO HYDROPHILIC CORONARY STENTS MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 195. NATO HYDROPHILIC CORONARY STENTS MARKET SIZE, BY ACUTE CORONARY SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 196. NATO HYDROPHILIC CORONARY STENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 197. NATO HYDROPHILIC CORONARY STENTS MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 198. GLOBAL HYDROPHILIC CORONARY STENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. UNITED STATES HYDROPHILIC CORONARY STENTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 200. UNITED STATES HYDROPHILIC CORONARY STENTS MARKET SIZE, BY STENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 201. UNITED STATES HYDROPHILIC CORONARY STENTS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 202. UNITED STATES HYDROPHILIC CORONARY STENTS MARKET SIZE, BY POLYMER MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 203. UNITED STATES HYDROPHILIC CORONARY STENTS MARKET SIZE, BY STENT SIZE, 2018-2032 (USD MILLION)
  • TABLE 204. UNITED STATES HYDROPHILIC CORONARY STENTS MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 205. UNITED STATES HYDROPHILIC CORONARY STENTS MARKET SIZE, BY ACUTE CORONARY SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 206. UNITED STATES HYDROPHILIC CORONARY STENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 207. UNITED STATES HYDROPHILIC CORONARY STENTS MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 208. CHINA HYDROPHILIC CORONARY STENTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 209. CHINA HYDROPHILIC CORONARY STENTS MARKET SIZE, BY STENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 210. CHINA HYDROPHILIC CORONARY STENTS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 211. CHINA HYDROPHILIC CORONARY STENTS MARKET SIZE, BY POLYMER MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 212. CHINA HYDROPHILIC CORONARY STENTS MARKET SIZE, BY STENT SIZE, 2018-2032 (USD MILLION)
  • TABLE 213. CHINA HYDROPHILIC CORONARY STENTS MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 214. CHINA HYDROPHILIC CORONARY STENTS MARKET SIZE, BY ACUTE CORONARY SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 215. CHINA HYDROPHILIC CORONARY STENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 216. CHINA HYDROPHILIC CORONARY STENTS MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)